C. Schmitt

Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU.

T. Hickish, E. Van Cutsem, E. Cutsem, 1999, European journal of cancer.

Aggressive chemotherapy in frail patients with diffuse large B-cell lymphoma: The role of pegylated liposomal doxorubicin

M. Scherrer-Crosbie, Lesley Smith, A. Avilés, 2012 .

Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin's lymphoma patients with cardiac risk factors

S. Dietrich, A. Ho, M. Witzens‐Harig, 2012, Annals of Hematology.

Diagnosis and Treatment of Nasopharyngeal Carcinoma in Children and Adolescents – Recommendations of the GPOH-NPC Study Group

F. Mottaghy, H. Christiansen, M. Eble, 2016, Klinische Pädiatrie.

Use of oral supplements in malnourished elderly patients living in the community: a pharmaco-economic study.

L Cynober, B. Beaufrère, D. Malvy, 2004, Clinical nutrition.

Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer.

I. Durand-zaleski, P. Piedbois, A. Bellanger, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

CXCL13 as a Novel Marker for Diagnosis and Disease Monitoring in Pediatric PTLD

C. Klein, L. Pape, H. Haller, 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer.

A. Bellanger, C. Schmitt, C. Lévy-Piedbois, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Medical care consumption in a phase III trial comparing irinotecan with infusional 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer after 5-FU failure.

P. Rougier, C. Schmitt, E. Cutsem, 1999, Anti-cancer drugs.

Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections

T. Harrer, L. Heinzerling, C. Blank, 2023, Cancer Immunology, Immunotherapy.